This was borne out in a Phase I clinical trial of G-CSF, plerixafor and sorafenib in FLT3-mutated relapsed/refractory AML (NCT00943943), where high response rates were seen even in patients who failed FLT3 inhibitors before [27]. Here, CSF3 is linked to acute myeloid leukemia.